MARKET

CODX

CODX

Co-Diagnostics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.85
-0.05
-0.56%
Opening 10:27 04/23 EDT
OPEN
8.79
PREV CLOSE
8.90
HIGH
8.97
LOW
8.71
VOLUME
92.68K
TURNOVER
--
52 WEEK HIGH
30.99
52 WEEK LOW
7.86
MARKET CAP
253.69M
P/E (TTM)
6.15
1D
5D
1M
3M
1Y
5Y
5 Health Care Stocks Trading with Low Price-Earnings Ratios
GuruFocus News · 1d ago
Proactive news headlines including Vuzix Corp, Cloud Nine Web3 Technologies, Fury Gold Mines and Dalrada Financial
New York, April 20, Apr 20, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, April 20, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video...
GlobeNewswire · 2d ago
Co-Diagnostics, Inc. Test Performance Demonstrated by Australian Researchers in Peer-Reviewed Publication
, /PRNewswire/ Co-Diagnostics, Inc.(Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit was used by Australian researchers to demo...
PR Newswire - PRF · 3d ago
How Biotech Developers Are Working Towards New Diagnostic Solutions to Combat Covid-19
Mar 31, 2021 (Financial News Media via COMTEX) -- FN Media Group Presents USA News Group News Commentary Vancouver, BC - March 31, 2021 – USA News Group – As...
Financial News Media · 03/31 12:57
Some Co-Diagnostics, Inc. (NASDAQ:CODX) Analysts Just Made A Major Cut To Next Year's Estimates
The analysts covering Co-Diagnostics, Inc. ( NASDAQ:CODX ) delivered a dose of negativity to shareholders today, by...
Simply Wall St. · 03/30 05:13
Co-Diagnostics Sales Will Slow, But the Stock Is Still a Buy, Says Analyst
Friday was not a fun day to be invested in Co-Diagnostics (CODX). Shares of the Coronavirus test maker sold off after the company reported fiscal Q4 and full-year 2020 financial results The good news is that Co-Diagnostics exceeded expectations for revenue...
TipRanks · 03/29 19:14
Co-Diagnostics cut to hold at Maxim questioning COVID-19 testing outlook
The analyst concerns over COVID-19 test makers continue as Maxim Group downgraded Co-Diagnostics ([[CODX]] -9.1%) to hold from buy arguing that the stock already reflects whatever the COVID-related benefit as
Seekingalpha · 03/29 17:02
Co-Diagnostics, DocuSign, Dow, Nomura, Sea and More Monday Afternoon Analyst Calls
247WallSt.com · 03/29 15:47
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CODX. Analyze the recent business situations of Co-Diagnostics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CODX stock price target is 23.00 with a high estimate of 30.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 112
Institutional Holdings: 8.16M
% Owned: 28.45%
Shares Outstanding: 28.67M
TypeInstitutionsShares
Increased
28
769.95K
New
17
433.69K
Decreased
22
951.14K
Sold Out
12
170.73K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.57%
Healthcare Equipment & Supplies
+0.38%
Key Executives
Chairman/President/Chief Executive Officer/Director
Dwight Egan
Chief Financial Officer
Brian Brown
Chief Technology Officer
Brent Satterfield
General Counsel/Secretary
Reed Benson
Independent Director
Eugene Durenard
Independent Director
Edward Murphy
Independent Director
James Nelson
Independent Director
Richard Serbin
No Data
  • All
  • Financials
  • Insiders
More
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

Webull offers kinds of Co-Diagnostics Inc stock information, including NASDAQ:CODX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CODX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CODX stock methods without spending real money on the virtual paper trading platform.